miR‑495 enhances the efficacy of radiotherapy by targeting GRP78 to regulate EMT in nasopharyngeal carcinoma cells

miR-495通过靶向GRP78调控鼻咽癌细胞EMT增强放射治疗疗效

阅读:4
作者:Xueping Feng, Wuwu Lv, Shuanglian Wang, Qian He

Abstract

Glucose‑regulated protein 78 (GRP78) was revealed to be associated with the radioresistance of nasopharyngeal carcinoma (NPC) in our previous study. GRP78 is a highly expressed cell surface protein, and holds great promise as a cancer specific target. Its expression may be impacted by the regulation of miRNAs, which may be involved in the radioresistance of NPC. A better understanding of the mechanisms of radioresistance may generate new targets of therapy for NPC patients. The present study was designed to investigate the effect of microRNA targeting GRP78 on the radiosensitivity of NPC. First, we used miRWalk software to predict miRNAs that may interact with GRP78. Subsequently, analysis of miR‑495 and GRP78 expression was performed in the primary tissues of 92 NPC tissues and cell lines by immunohistochemistry and real‑time PCR and the results revealed that miR‑495 expression was lower in radioresistant NPC tissues in comparison to chronic rhinitis tissues, and also lower in radioresistant 5‑8F cells (5‑8F‑IR) in comparison to its parental 5‑8F cells. Notably, we observed an inverse association between the expression miR‑495 and GRP78. Our bioinformatics analysis led to the identification of miR‑495 as the optimal miRNA interacting with GRP78 mRNA. Furthermore, miR‑495 targeting the 3'untranslated region (UTR) of GRP78 was detected by a Dual‑Glo Luciferase Assay system. Finally, we observed that miR‑495 inhibition led to a significant increase in the radioresistance of 5‑8F cells and higher GRP78 expression, which may be involved in epithelial‑mesenchymal transition (EMT) phenotype. miR‑495 targeted the 3'UTR of GRP78 and contributed to the efficacy of radiation therapy in NPC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。